Which itself raise a major concern if this "esteem" management is having problem commercialising the product. Like I always said, it all about the technology's market and whether there's limitation and unfortunately the product isn't totally objective with only the facial assessment required.
No doubt some RCA will find Painchek useful either because they find the facial assessment of the APS difficult to conduct or they like the digitalisation of the process or both but clearly a majority doesn't as Painchek has and will always be competing with APS since 5 out of the 6 APS assessments still need to be done manually.
Painchek tried to commercialise globally well before the pandemic, are you forgetting Singapore, NZ and UK announcement????
PCK Price at posting:
2.6¢ Sentiment: None Disclosure: Not Held
